Albert Bourla, Pfizer CEO (Evan Vucci/AP Images)

Amid rev­enue dip, Pfiz­er CEO Al­bert Bourla is fo­cused on 'what's nex­t'

Pfiz­er suf­fered its first quar­ter­ly rev­enue dip since its BioN­Tech-part­nered Covid vac­cine was au­tho­rized in 2020, CEO Al­bert Bourla re­vealed on Tues­day. And if that isn’t bad enough, he ex­pects patent ex­piries to cost the com­pa­ny around $17 bil­lion be­tween 2025 and 2030.

Which is why, he em­pha­sized on the Q3 call, “It’s all about what’s next.”

Bourla out­lined am­bi­tious plans to bring 19 new prod­ucts or in­di­ca­tions to mar­ket over the next year and a half.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.